newsfilter
← Earnings
Earnings Releases·

Larimar Therapeutics — Third Quarter 2026 Earnings Summary

Larimar Therapeutics completed a rolling Biologics License Application submission seeking accelerated approval for nomlabofusp to treat Friedreich's ataxia, utilizing skin frataxin as a potential novel surrogate endpoint. The company reported a net loss of $31.1 million for the third quarter of 2026, a decrease from $47.7 million in the same period the prior year, driven largely by reduced drug manufacturing expenses. As of September 30, 2026, Larimar held $128.7 million in cash and marketable securities, projecting a runway into late Q2 2027. The company is currently enrolling patients in the global confirmatory Phase 3 FORWARD-FA study and targets a potential U.S. launch in the third quarter of 2027 if the application is approved.

Company
LARIMAR THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology